Becton Dickinson and Company (BDX) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

Medical Supplies, Laboratory Equipment, Diagnostic Products

Becton, Dickinson and Company is a leading global medical technology company that develops, manufactures, and sells a wide range of medical supplies, devices, laboratory equipment, and diagnostic products. These products are designed to cater to various healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment focuses on providing a broad portfolio of products, including peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. Additionally, they offer vascular care and preparation products, needle-free IV connectors and extension sets, closed-system drug transfer devices, and hazardous drug detection systems. They also provide hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems.

Furthermore, the BD Medical segment offers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems. They also provide prefillable drug delivery systems, which enable safe and efficient administration of medications.

The BD Life Sciences segment is dedicated to providing a range of products and solutions for life science researchers, clinical laboratories, and pharmaceutical companies. Their offerings include specimen and blood collection products, automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems. They also offer rapid diagnostic assays, microbiology laboratory automation products, and plated media products. Moreover, they provide fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

The BD Interventional segment focuses on providing a range of surgical and interventional products, including hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products. They also offer surgical infection prevention products, peripheral intervention products, and urology and critical care products.

Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey. With a rich history and a strong commitment to innovation, the company continues to develop and provide innovative medical solutions that improve healthcare outcomes and patient care.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Becton Dickinson and Company (BDX) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Becton Dickinson and Company (BDX) - Stock & Dividends

BDX Stock Overview

Market Cap in USD 69,411m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC SubIndustry Health Care Equipment
TER 0.00%
IPO / Inception 1987-01-01

BDX Stock Ratings

Growth 5y 2.92
Fundamental 15.4
Dividend 5.52
Rel. Performance vs Sector -1.96
Analysts 4.17/5
Fair Price Momentum 212.43 USD
Fair Price DCF 286.98 USD

BDX Dividends

Yield 12m 1.62%
Yield on Cost 5y 1.69%
Dividends CAGR 5y 4.02%
Payout Consistency 79.2%

BDX Growth Ratios

Growth 12m -7.83%
Growth Correlation 12m -51%
Growth Correlation 3m -31%
CAGR 5y 0.86%
CAGR/Mean DD 5y 0.09
Sharpe Ratio 12m -0.65
Alpha vs SP500 12m -23.65
Beta vs SP500 5y weekly 0.50
ValueRay RSI 42.63
Volatility GJR Garch 1y 20.67%
Price / SMA 50 -0.59%
Price / SMA 200 -3.62%
Current Volume 701.4k
Average Volume 20d 1571.7k

External Links for BDX Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of BDX stocks?
As of June 18, 2024, the stock is trading at USD 232.75 with a total of 701,414 shares traded.
Over the past week, the price has changed by -2.82%, over one month by -1.11%, over three months by -1.70% and over the past year by -8.60%.
What are the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson and Company will be worth about 231.3 in June 2025. The stock is currently trading at 232.75. This means that the stock has a potential downside of -0.62%.
Issuer Forecast Upside
Wallstreet Target Price 276.7 18.9
Analysts Target Price 301.2 29.4
ValueRay Target Price 231.3 -0.62

The History and Market Status of Becton Dickinson and Company (BDX)

A Brief History

Becton, Dickinson and Company, commonly known as BD, began its journey in 1897. Founded by Maxwell Becton and Fairleigh S. Dickinson, its initial aim was to improve and simplify the process of delivering medications. Starting with glass syringes, BD has significantly grown, enhancing not only the medical field but also healthcare delivery globally. The company achieved many milestones over the years, like the development of the first-ever insulin syringe in 1924, and it has continued innovating in medical technology effectively till today.

Core and Side Businesses

BD's core mission revolves around advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. Its operations span across multiple segments:

  • Medical: Produces devices for medication delivery, diabetes care, and surgical instrument sterilization.
  • Life Sciences: Offers products for collecting and transporting diagnostics specimens, and instruments for cell analysis.
  • Interventional: Focuses on surgery, peripheral intervention, and urology and critical care treatments.

Alongside its primary operations, BD also collaborates with organizations worldwide to tackle global health issues, such as combating antimicrobial resistance and supporting health research and clinical diagnostics.

Current Market Status

As of 2023, BD (NYSE:BDX) continues to hold a significant position in the medical technology industry. Despite the challenges, such as regulatory pressures and global health crises, BD has shown resilience and adaptability. It continues to invest in research and development, aiming to bring forth innovations that can make a real difference in healthcare. The company's commitment to sustainability and addressing global health issues also adds to its reputation, potentially offering a competitive edge in the market. Financially, BD has maintained a steady performance, although the rapidly changing healthcare landscape calls for continuous innovation and strategic partnerships to sustain and enhance its market presence.